Skip to main content
Premium Trial:

Request an Annual Quote

Agenix, Arrayjet Leveraging Microarray Technology to Develop POC Testing Platform

NEW YORK (GenomeWeb News) – Australian diagnostics and drug firm Agenix today announced a cooperation and cross-licensing deal with Arrayjet to jointly develop a point-of-care testing platform into a multiplex testing and screening system.

The two companies plan to develop a test based on Agenix's flow through DiagnostIQ POCT platform but with the "sensitivity, accuracy, and multiplexing ability of planar microarray technology," they said.

DiagnostIQ is a disposable point-of-care test device, which uses an antibody/antigen printed membrane, a filter device, and an incubation chamber in a flow-through format. The new test being developed will leverage Roslin, Scotland-based Arrayjet's non-contact inkjet microarray printing technology.

Development costs will be paid partially through research grants and access to R&D tax incentives, the two companies said.

"Partnering with Arrayjet is an important step in the development of our DiagnostIQ licensed technology for human health applications," Agenix Chairman and CEO Nick Weston said in a statement. "There is a high unmet medical need for a platform able to do multiplexed affinity-based assays in low-resource or mobile settings."

Arrayjet CEO Iain McWilliam added, "We see the vertical flow, disposable cartridge at the heart of the DiagnostIQ platform as the ideal vehicle for a multiplex diagnostics array. Our eventual aim will be to offer customers an end-to-end process, whereby they can rapidly translate a novel biomarker profile into a diagnostic tool presented on a reformatted version of DiagnostIQ to afford the end user a simple to use, cost effective solution.

Financial and other terms were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.